Lisa Butterfield, Ph.D.
Department of Medicine
University of Pittsburgh
HCC Suite 1.27
5117 Centre Avenue
Pittsburgh, PA 15213
The Butterfield lab focuses on cross-talk between tumor antigens and the immune system in melanoma and hepatocellular cancer patients. In melanoma vaccine trials, we find that frequency and function of vaccine-induced MART-1-specific T cells is unrelated to clinical outcome, but that broadening of the immune response to include additional antigens expressed by tumors is correlated with clinical outcome. Currently, we are investigating multiple-defined antigen-based vaccine strategies and methods for incorporating innate effector (Natural Killer cell) activation. By understanding these immune responses, improved vaccines can be rationally designed that specifically initiate antigenically broad immunity, encompassing CD8 and CD4 T cells, capable of full effector and memory function.
Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH (2010). Virally-infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. Blood, in press.
Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, Whiteside TL, Butterfield LH, Weiner L (2009). Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 15: 1443-1451.
Butterfield LH, et al. (2008). A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”. J. Transl Med. 6: 81.
Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH (2009). Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother. 58: 121-133.